Devon, PA, June 30, 2015 – Zynerba Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.
Jefferies LLC and Piper Jaffray & Co. will act as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. will act as co-managers for the offering.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering will be made only by means of a prospectus. When available, a copy of the prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388, or by email at Prospectus_Department@Jefferies.com, or by accessing the SEC’s website at www.sec.gov.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is a privately held ten-year-old specialty pharmaceutical company focusing on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery.
Investor Contact:
Armando Anido
Chairman and CEO
Zynerba Pharmaceuticals
484.581.7505
Media Contact:
Jennifer Guinan
Sage Strategic Marketing
610.410.8111
Jennifer@sagestrat.com